Aims: To evaluate whether the metabolic syndrome (MetS) defined by the International Diabetes Federation (IDF) criteria, which has abdominal adiposity as a mandatory element, predicts cardiovascular disease (CVD) mortality better than the cluster of other IDF-defined abnormalities not including abdominal adiposity. Methods: Data from nine European population-based studies, including 7782 men and 7739 women (aged 30-89 years), with a median follow-up of 8.55 years, were jointly analyzed. Hazard ratios for CVD mortality were calculated with Cox regression models. Results: In total, 41% of the men and 38% of the women had the IDF MetS. Individuals with the IDF MetS were by definition more obese and had a higher prevalence of diabetes than non-obese subjects with X2 IDF abnormalities; whereas non-obese men with X3 factors had more atherogenic lipid profiles. Multivariate adjusted hazard ratio for CVD death in men and women with the IDF MetS was 2.44 (1.69-2.98) and 2.32 (1.27-4.23); in non-obese men with 2 and X3 factors the hazard ratio was 1.60 (1.12-2.30) and 2.44 (1.62-3.66), respectively, and in non-obese women with 2 factors the hazard ratio was 2.41 (1.09-5.33). Conclusions: The cluster of the CVD risk factors predicted CVD mortality regardless of the presence or absence of the abdominal adiposity. Inclusion of abdominal adiposity as a prerequisite will miss those non-obese individuals who have increased CVD mortality.
Introduction
The International Diabetes Federation (IDF) proposed a new criteria for the metabolic syndrome (MetS) during the First International Congress on Prediabetes and Metabolic Syndrome on 14 April 2005. 1 These new IDF diagnostic criteria emphasized the importance of abdominal adiposity, as measured by waist circumference, considering it as a prerequisite for the definition; an ethnically specific waist cutoff value for abdominal adiposity and a low fasting plasma glucose cutoff value for impaired fasting glucose were recommended. The IDF recommendation reflects the fact that obesity is the common component of the MetS and together with insulin resistance might be one of the underlying causes of the MetS. 1 It is, however, still unknown whether the cluster of cardiovascular disease (CVD) risk factors included in the definition of the MetS with abdominal adiposity has a different CVD mortality from that without obesity. This question was studied using the data from nine European Studies participating in the Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe (DECODE) study.
Study populations and methods
The recruitment of the DECODE study has been described in detail previously. [2] [3] [4] [5] [6] [7] [8] Briefly, researchers who had performed European epidemiological studies on diabetes and abnormalities of glucose homeostasis, using a standard 2-h 75 g oral glucose tolerance test, were invited to participate. Individual data on fasting and 2-h glucose concentrations and a number of other variables were sent to the Diabetes and Genetic Epidemiology Unit of the National Public Health Institute in Helsinki, Finland, for the collaborative data analyses. All the studies involved in DECODE study were approved by the local ethical committee and informed consent was collected by the each centers. Agreement for the collaborating data analyses was collected from each center with the signature of the principal investigator.
All the studies included in the current data analysis (Appendix 1 Table A1 ) are population-based. Except Uppsala study which only recruited men, all the studies comprised men and women. The CVD mortality was uniformly classified according to the International Classification of Disease 9 or 10. The glucose oxidase method for blood glucose and enzymatic method for lipid were applied in all study laboratories (Appendix 1 Table A1 ). Waist circumference was measured at the midway between the lower rib margin and iliac crest in all except the Cremona study, where it was measured at the level of umbilicus. Although the questionnaire to record the smoking status varied among centers, smoking status can be classified into non-smoker, current smoker or ex-smoker according to self-reported information.
Classification of subjects
Because the data on lipid-lowering medication was not available, a modified rather than the original IDF definition for the MetS was applied in the current study. Individuals were considered as having the IDF MetS if they had abdominal adiposity (waist girth X94 cm in men or X80 cm in women for Europid) plus any two of the following four abnormalities:
(1) Raised triglycerides: serum triglycerides X1.7 mM; (2) reduced high-density lipoprotein cholesterol (HDL-c):
HDL-c o1.03 mM in men and o1.29 mM in women; (3) raised blood pressure: systolic blood pressure X130 mm Hg and/or diastolic blood pressure X85 mm Hg, or drug treatment of previously diagnosed hypertension and (4) raised fasting plasma glucose: fasting plasma glucose X5.6 mM, or previously diagnosed type 2 diabetes.
Diabetes was defined as individuals with a prior history of diabetes or with fasting plasma glucose X7.0 mM and/or 2-h post-challenge glucose X11.1 mM. 9 
Statistical analysis
Because of the skewed distribution, plasma glucose, triglyceride and HDL-c were logarithmically transformed to get a near normal distribution and the geometric means were presented. The difference between groups was tested with analysis of variance and means were calculated with general linear model adjusting for age and study. The Cox proportional hazard model adjusted for age, study, serum cholesterol and smoking was performed to estimate hazard ratios for CVD death associated with the different clusters of metabolic abnormalities. All data analyses were performed with the SPSS for Windows 15.0 software package.
Results
A total of 15 521 subjects (7782 men and 7739 women) from nine studies participating in the DECODE study formed the present study population ( Table 1 ). The mean age of study participants ranged from 47 to 71 years. The baseline examination was carried out around the beginning of 1990s, except for FINRISK 2002. The maximum length of follow-up ranged from 3.9 to 20.6 years. A total of 564 participants (436 men) died of CVD during the follow-up.
The IDF criteria defined 53.9% men and 62.9% women of the study population as having abdominal adiposity, and the prevalence of the IDF MetS was 41.2% in men and 37.9% in women (Table 2 ). In all, 20.3% men and 9.5% women had two or more abnormalities but without abdominal adiposity. Non-obese individuals with 3-4 (out of four) IDF MetS risk factors were rare.
Non-obese individuals with two IDF metabolic abnormalities had worse cardiovascular risk profiles than the nonobese subjects with one abnormality or less, but more favorable than those with the IDF MetS (Tables 2 and 3) . Subjects with the IDF MetS were, by definition, more obese and also had higher blood pressure than the non-obese 
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In non-obese men, the multivariate adjusted hazard ratio increased significantly with increasing number of factors clustered from 2 to 3-4 as compared with non-obese men with p1 factor (reference group). This was also observed for non-obese women with two factors (Table 4) . Compared with people with the IDF MetS, the hazard ratio was lower for non-obese men with two factors (0.45, 95% CI 0.34-0.59), but was not significantly different for non-obese men with 3-4 factors (1.09, 95% CI 0.77-1.54) and for non-obese women with two factors (1.04, 95% CI 0.58-1.92).
Discussion
Both the abdominal adiposity and IDF MetS were common in this study population, and the IDF MetS identified people with increased CVD mortality. Non-obese people with two or more IDF MetS factors were less prevalent, but they had higher CVD mortality compared with that in non-obese individuals with less IDF MetS Metabolic abnormalities defined by the IDF criteria, which include: (I) blood pressure X130/85 mm Hg or treated hypertension; (II) triglyceride X1.7 mM; (III) HDL-cholesterol o1.03 mM in men and o1.29 mM in women and (IV) fasting plasma glucose X5.6 mM or previously diagnosed diabetes. Po0.05, *compared with non-obese subjects with p1 abnormalities, w compared with subjects with the IDF MetS. The definition of the MetS aims at identifying high-risk individuals for CVD and type 2 diabetes. 1 However, evidence from studies that have assessed the association between the MetS and CVD risk is not consistent. 10 Some of them indicated that the MetS, defined with National Cholesterol Education Program (NCEP) or WHO criteria, is associated with significantly increased CVD risk, and might be a useful predictor for CVD events. [11] [12] [13] [14] There are, however, also reports suggesting that the MetS did not convey a high CVD risk or had less power in predicting CVD events than the individual metabolic abnormality. [15] [16] [17] [18] [19] [20] Our study revealed that the IDF criteria of the MetS predicted CVD mortality. By definition, subjects who did not have abdominal adiposity but had at least two other factors were not identified by the IDF criteria, while CVD mortality in such men was as high as in those with the IDF MetS even after adjusting age, smoking status and total serum cholesterol. In all, CVD deaths occurred in 22% men and 9% women in these nonobese individuals. The evidence from the present study suggests that the criteria without making a mandatory condition would be more inclusive of individuals with increased CVD mortality.
In this study population, non-obese men with two or more metabolic abnormalities had a higher prevalence of smoking than others. To check to what extent smoking has contributed to the increased CVD mortality in these men, stratified data analyses by smoking status were carried out. The hazard ratios for CVD mortality in non-obese men with two or more metabolic abnormalities as compared with non-obese men with zero or one abnormality were 1.83 (1.11-3.01) in smokers and 1.87 (1.09-3.23) in non-smokers. The corresponding figures in individuals with the IDF MetS were 2.21 (1.39-3.49) in smokers and 2.42 (1.52-3.84) in non-smokers, respectively. The results suggested that the increased CVD mortality could not be fully attributed to smoking status.
The merit of the collaborative data analysis is that the studies included in the current data analysis are all population-based and represent the general population of individual study location. The statistical power is higher than that of any single study alone, which can answer questions that may not be addressed in an individual study. The major problem of the collaborative data analysis is whether the data collected or the effect size is homogeneous since each study had been carried out individually using different protocols. We noticed, however, that laboratory analyses for glucose and lipids and the measurement of waist happened to be quite homogenous. And, the CVD mortality has been uniformly classified according to the International Classification of Disease. Moreover, a statistic measuring study-to-study variation showed that the effect size was not statistically different from zero (P40.10). 21 In addition, adjustment for study was done in all the data analyses using pooled data.
In conclusion, the cluster of the CVD risk factors predicted CVD mortality regardless of whether the abdominal adiposity was present or not. Inclusion of abdominal adiposity as a prerequisite will miss many non-obese individuals who have increased CVD mortality. 
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